BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is hosting its Investor Day on September 4, 2024, in New York, starting at 10:30 a.m. Eastern Time. The event, led by President and CEO Alexander Hardy, will showcase the company's new strategic priorities aimed at delivering significant value creation.
Key presentations include:
- BioMarin's new corporate strategy for sustained value creation
- Financial strategy for high growth and superior returns
- Innovation strategy for a sustainable pipeline of high-impact medicines
- Commercial growth strategy, focusing on enzyme therapies and leadership in achondroplasia
The event will be accessible virtually, with a live webcast, replay, and presentation slides available on BioMarin's Investor Relations website for at least 12 months.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ospiterà il suo Investor Day il 4 settembre 2024 a New York, con inizio alle 10:30 ora orientale. L'evento, guidato dal Presidente e CEO Alexander Hardy, presenterà le nuove priorità strategiche dell'azienda, mirate a garantire una significativa creazione di valore.
Le presentazioni principali includono:
- La nuova strategia aziendale di BioMarin per una creazione di valore sostenuta
- Strategia finanziaria per una crescita elevata e rendimenti superiori
- Strategia di innovazione per un portafoglio sostenibile di medicinali ad alto impatto
- Strategia di crescita commerciale, concentrandosi sulle terapie enzimatica e sulla leadership nell'achondroplasia
L'evento sarà accessibile virtualmente, con una diretta streaming, registrazione e slide della presentazione disponibili sul sito delle Relazioni con gli Investitori di BioMarin per almeno 12 mesi.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) llevará a cabo su Investor Day el 4 de septiembre de 2024 en Nueva York, comenzando a las 10:30 a.m. hora del este. El evento, liderado por el Presidente y CEO Alexander Hardy, presentará las nuevas prioridades estratégicas de la empresa, dirigidas a generar una creación de valor significativa.
Las presentaciones clave incluirán:
- La nueva estrategia corporativa de BioMarin para una creación de valor sostenida
- Estrategia financiera para un crecimiento elevado y retornos superiores
- Estrategia de innovación para un pipeline sostenible de medicamentos de alto impacto
- Estrategia de crecimiento comercial, centrada en terapias enzimáticas y liderazgo en achondroplasia
El evento será accesible virtualmente, con una transmisión en vivo, repetición y diapositivas de la presentación disponibles en el sitio web de Relaciones con Inversores de BioMarin durante al menos 12 meses.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)은 2024년 9월 4일 뉴욕에서 오전 10시 30분(동부 표준시)에 Investor Day를 개최합니다. 알렉산더 하르디 CEO가 이끄는 이번 행사에서는 회사의 새로운 전략적 우선 사항이 소개되어 상당한 가치 창출을 목표로 하고 있습니다.
주요 발표 내용은 다음과 같습니다:
- 지속 가능한 가치 창출을 위한 BioMarin의 새로운 기업 전략
- 고성장 및 우수한 수익을 위한 재무 전략
- 고위험 의약품의 지속 가능한 파이프라인을 위한 혁신 전략
- 효소 요법 및 왜소증(achondroplasia)에서의 리더십에 중점을 둔 상업적 성장 전략
이번 행사는 라이브 웹캐스트와 재생, 프레젠테이션 슬라이드가 BioMarin의 투자자 관계 웹사이트에서 최소 12개월 동안 제공될 예정입니다.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) tiendra son Investor Day le 4 septembre 2024 à New York, à partir de 10h30, heure de l'Est. L'événement, dirigé par le Président et CEO Alexander Hardy, présentera les nouvelles priorités stratégiques de l'entreprise visant à créer une valeur significative.
Les présentations clés incluent :
- La nouvelle stratégie d'entreprise de BioMarin pour une création de valeur durable
- Stratégie financière pour une forte croissance et des retours supérieurs
- Stratégie d'innovation pour une pipeline durable de médicaments à fort impact
- Stratégie de croissance commerciale, axée sur les thérapies enzymatiques et le leadership dans l'achondroplasie
L'événement sera accessible virtuellement, avec un webinaire en direct, un replay et des diapositives de présentation disponibles sur le site des relations investisseurs de BioMarin pendant au moins 12 mois.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) veranstaltet am 4. September 2024 in New York seinen Investor Day, der um 10:30 Uhr Eastern Time beginnt. Die Veranstaltung, geleitet von Präsident und CEO Alexander Hardy, wird die neuen strategischen Prioritäten des Unternehmens präsentieren, die auf die Schaffung erheblicher Werte abzielen.
Wichtige Präsentationen umfassen:
- Die neue Unternehmensstrategie von BioMarin zur nachhaltigen Wertschöpfung
- Finanzstrategie für hohes Wachstum und überlegene Renditen
- Innovationsstrategie für eine nachhaltige Pipeline von hochwirksamen Medikamenten
- Wachstumsstrategie im Handel, mit Fokus auf Enzymtherapien und Führungsposition im Bereich Achondroplasie
Die Veranstaltung wird virtuell zugänglich sein, mit einem Live-Streaming, einer Wiederholung und Präsentationsfolien, die mindestens 12 Monate lang auf der Website der Investor Relations von BioMarin verfügbar sein werden.
- None.
- None.
Led by President and Chief Executive Officer Alexander Hardy, the event will feature presentations from BioMarin's leadership team as they introduce strategic priorities that underscore BioMarin's commitment to deliver significant value creation. A question-and-answer session will follow prepared remarks.
BioMarin's Investor Day Agenda:
- BioMarin's New Corporate Strategy to Deliver Significant and Sustained Value Creation to Stakeholders
Alexander Hardy, President and Chief Executive Officer - Value Commitment: Financial Strategy to Deliver High Growth and Superior Returns
Brian Mueller, Executive Vice President, Chief Financial Officer - Innovation Strategy to Deliver Sustainable Pipeline of High Impact Medicines
Hank Fuchs, M.D., President, Worldwide R&D - Commercial Growth Strategy:
- o Optimizing BioMarin's Growing and Durable Enzyme Therapies Business Unit
- o Building Leadership in Achondroplasia to Set the Stage for Multiple New Indications
Cristin Hubbard, Executive Vice President, Chief Commercial Officer
A link to the live webcast, replay and presentation slides will be available on BioMarin's Investor Relations website for at least 12 months at investors.biomarin.com.
About BioMarin
Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com.
Contacts: | |
Investors | Media |
Traci McCarty | Marni Kottle |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (415) 218-7111 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-host-investor-day-today-at-1030-am-eastern-time-302237727.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
When is BioMarin (BMRN) hosting its Investor Day in 2024?
What key topics will be covered during BioMarin's (BMRN) Investor Day?
How can investors access BioMarin's (BMRN) Investor Day event?
Who will be leading the presentations at BioMarin's (BMRN) Investor Day?
